Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trialChristopher Koh, Theo Heller, David E. Kleiner et al.|The Lancet Infectious Diseases|2015Cited by 262
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 studyCihan Yurdaydın, Jeffrey S. Glenn, Çağdaş Kalkan et al.|Hepatology|2017Cited by 150